Description
Join Joanne Rinker, MS, RDN, BC-ADM, CDCES, FADCES, as she reviews topline data from INHALE-3, a recent head-to-head study of AFREZZA vs Usual Care (multiple daily injections* [MDI] and automated insulin delivery [AID]) in adults with type 1 diabetes. AFREZZA is the only rapid-acting inhaled mealtime insulin indicated to improve glycemic management in adult patients with diabetes mellitus.
This in-depth session will reveal groundbreaking findings from the INHALE-3 study. Learn how transitioning from multiple daily injections or automated insulin delivery to AFREZZA has affected A1C levels, time in range, and pulmonary safety. Don't miss this opportunity to gain valuable insights and be part of a revolutionary change in diabetes management. Register now to be at the forefront of innovation!
*Includes non-automated pumps
This 45-minute activity was originally presented on 5/21/2025.
Sponsor
This webinar is sponsored by MannKind.
Intended Audience
This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, PAs, physicians, and other health care providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.
Disclaimer
This educational program does not provide certification on the product discussed. There is no CE/CME credit for this activity.